At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also progresses its second HDACi asset, CS014, toward Phase 2. Cereno's developing pioneering treatments with disease-modification potential for rare cardiovascular and pulmonary diseases.---Learn more about Cereno: https://bit.ly/cereno-e52---⭐️ ABOUT THE SPEAKERSten joined Cereno as CEO in 2015, with decades of experience ...
At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also progresses its second HDACi asset, CS014, toward Phase 2. Cereno's developing pioneering treatments with disease-modification potential for rare cardiovascular and pulmonary diseases.---Learn more about Cereno: https://bit.ly/cereno-e52---
⭐️ ABOUT THE SPEAKER
Sten joined Cereno as CEO in 2015, with decades of experience in pharma, ranging from Monsanto Pharma to AstraZeneca.
🔗 LINKS MENTIONED
- Cereno’s website - https://cerenoscientific.com/
- Cereno Scientific | BioStock Life Science Summit 2024 - [https://www.youtu.be/A5b3Ud_PSas](https://www.youtube.com/watch?v=A5b3Ud_PSas)
- Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension **-** https://cerenoscientific.com/press-single/?releaseIdentifier=2D7F159764FDB891
- Cereno's HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial **-** https://www.fiercebiotech.com/biotech/cerenos-hdac-inhibitor-reduces-risks-pulmonary-arterial-hypertension-phase-2-trial
- Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH) - https://cerenoscientific.com/press-single/?releaseIdentifier=008944355F62DA91
- Competing drug Winrevair / sotatercept by US Merck - https://www.drugs.com/winrevair.html
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/sten-sorensen-cereno-drug-repurposing/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
- [00:00:00] Intro
- [00:02:04] Cereno's Phase2A results
- [00:21:59] Phase2B
- [00:32:41] Cereno's pipeline
- [00:40:56] The finances of running a Phase2B
- [00:45:07] Investor base of Cereno
- [00:50:42] A strong team is crucial for Cereno
- [00:55:41] The Swedish biotech ecosystem
- [01:02:54] Sten Sörensen's background
- [01:10:39] Success in drug repurposing
- [01:16:03] Quickfire
View more